Quantitative MRI for Early Treatment Response in MASLD.
作者信息
Yin Meng
机构信息
Department of Radiology, Mayo Clinic, 200 First St SW, Rochester, MN 55905.
出版信息
Radiology. 2025 Aug;316(2):e252218. doi: 10.1148/radiol.252218.
Abstract
摘要
相似文献
1
Quantitative MRI for Early Treatment Response in MASLD.用于评估非酒精性脂肪性肝病早期治疗反应的定量磁共振成像
Radiology. 2025 Aug;316(2):e252218. doi: 10.1148/radiol.252218.
2
Inflammatory markers as diagnostic and precision nutrition tools for metabolic dysfunction-associated steatotic liver disease: Results from the Fatty Liver in Obesity trial.炎症标志物作为代谢功能障碍相关脂肪性肝病的诊断和精准营养工具：来自肥胖相关性脂肪肝试验的结果。
Clin Nutr. 2024 Jul;43(7):1770-1781. doi: 10.1016/j.clnu.2024.05.042. Epub 2024 May 31.
3
Impact of alcohol consumption and muscle mass on bone mineral density in metabolic dysfunction and alcohol-associated liver disease (MetALD) and metabolic dysfunction-associated steatotic liver disease (MASLD).饮酒量和肌肉量对代谢功能障碍与酒精相关肝病（MetALD）及代谢功能障碍相关脂肪性肝病（MASLD）患者骨密度的影响。
Clin Nutr ESPEN. 2025 Jul 7;69:145-153. doi: 10.1016/j.clnesp.2025.07.002.
4
Screening for MASLD in patients with type 2 diabetes: is an early diagnosis a good diagnosis?2型糖尿病患者中MAFLD的筛查：早期诊断就是好诊断吗？
Expert Rev Gastroenterol Hepatol. 2025 Sep;19(9):941-951. doi: 10.1080/17474124.2025.2546597. Epub 2025 Aug 19.
6
Proton density fat fraction for diagnosis of metabolic dysfunction-associated steatotic liver disease.用于诊断代谢功能障碍相关脂肪性肝病的质子密度脂肪分数
Hepatology. 2025 Mar 25. doi: 10.1097/HEP.0000000000001318.
7
Weight gain in infancy and metabolic dysfunction-associated steatotic liver disease (MASLD) in a prospective birth cohort of Latino children.拉丁裔儿童前瞻性出生队列中的婴儿期体重增加与代谢功能障碍相关脂肪性肝病（MASLD）
Matern Health Neonatol Perinatol. 2025 Aug 15;11(1):25. doi: 10.1186/s40748-025-00225-8.
8
(-)Epicatechin targets early growth response protein 1, an inflammation-associated ferroptosis regulator, to ameliorate metabolic dysfunction-associated steatotic liver disease.（-）表儿茶素靶向早期生长反应蛋白1，一种与炎症相关的铁死亡调节因子，以改善代谢功能障碍相关的脂肪性肝病。
Biochem Pharmacol. 2025 Jul 4;240:117100. doi: 10.1016/j.bcp.2025.117100.
9
Validation of FIB-4 for the Diagnosis of Liver Cirrhosis in Metabolic Dysfunction-Associated Steatotic Liver Disease.FIB-4在代谢功能障碍相关脂肪性肝病肝硬化诊断中的验证
Can Liver J. 2025 Feb 12;8(2):280-283. doi: 10.3138/canlivj-2024-0063. eCollection 2025 May.
10
Impact of weight loss and lifestyle modifications on liver fibrosis in MASLD and MetALD: A cohort study.体重减轻和生活方式改变对代谢相关脂肪性肝病（MASLD）和代谢相关脂肪性肝炎（MetALD）肝纤维化的影响：一项队列研究。
Biomed Rep. 2025 Jul 25;23(4):158. doi: 10.3892/br.2025.2036. eCollection 2025 Oct.
本文引用的文献
1
Multiparametric MRI Evaluation of Liver Fat and Iron after Glucagon-like Peptide-1 Receptor and Glucagon Receptor Dual-Agonist Treatment in a High-Fat Diet-induced Mouse Model.在高脂饮食诱导的小鼠模型中，胰高血糖素样肽-1受体和胰高血糖素受体双重激动剂治疗后肝脏脂肪和铁的多参数MRI评估
Radiology. 2025 Aug;316(2):e243780. doi: 10.1148/radiol.243780.
2
Multi-Center, Multi-Vendor Validation of Simultaneous MRI-Based Proton Density Fat Fraction and R2* Mapping Using a Combined Proton Density Fat Fraction-R2* Phantom.使用联合质子密度脂肪分数-R2*体模对基于MRI的同步质子密度脂肪分数和R2*成像进行多中心、多供应商验证
J Magn Reson Imaging. 2025 Apr 18. doi: 10.1002/jmri.29775.
3
Extracellular Vesicles miRNome Profiling Reveals miRNAs Engagement in Dysfunctional Lipid Metabolism, Chronic Inflammation and Liver Damage in Subjects With Metabolic Dysfunction-Associated Steatotic Liver Disease.细胞外囊泡微小RNA组分析揭示微小RNA参与代谢功能障碍相关脂肪性肝病患者的脂质代谢异常、慢性炎症和肝损伤
Aliment Pharmacol Ther. 2025 Jul;62(1):22-32. doi: 10.1111/apt.70150. Epub 2025 Apr 10.
4
Three-Dimensional Vector MR Elastography for Evaluating Tissue Mechanical Heterogeneity to Assess Liver Disease Progression.用于评估组织力学异质性以评估肝脏疾病进展的三维矢量磁共振弹性成像
Radiology. 2025 Apr;315(1):e242349. doi: 10.1148/radiol.242349.
5
Addressing the High and Rising Global Burden of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-Associated Steatohepatitis (MASH): From the Growing Prevalence to Payors' Perspective.应对代谢功能障碍相关脂肪性肝病（MASLD）和代谢功能障碍相关脂肪性肝炎（MASH）日益加重的全球负担：从患病率上升到支付方视角
Aliment Pharmacol Ther. 2025 May;61(9):1467-1478. doi: 10.1111/apt.70020. Epub 2025 Feb 18.
6
Resmetirom therapy for metabolic dysfunction-associated steatotic liver disease: October 2024 updates to AASLD Practice Guidance.用于代谢功能障碍相关脂肪性肝病的瑞美替隆疗法：美国肝病研究学会实践指南2024年10月更新
Hepatology. 2025 Jan 1;81(1):312-320. doi: 10.1097/HEP.0000000000001112. Epub 2024 Oct 18.
7
Impact of age on NIS2+™ and other non-invasive blood tests for the evaluation of liver disease and detection of at-risk MASH.年龄对NIS2+™及其他用于评估肝病和检测高危代谢相关脂肪性肝病（MASH）的非侵入性血液检测的影响
JHEP Rep. 2024 Jan 19;6(4):101011. doi: 10.1016/j.jhepr.2024.101011. eCollection 2024 Apr.
8
Computed tomography-based evaluation of segmental variation of liver density and its implications.基于计算机断层扫描的肝脏密度节段性变异评估及其意义。
Indian J Gastroenterol. 2020 Feb;39(1):60-65. doi: 10.1007/s12664-019-01008-8. Epub 2020 Mar 10.
9
Inter-examination precision of magnitude-based MRI for estimation of segmental hepatic proton density fat fraction in obese subjects.基于量级的磁共振成像在肥胖受试者中评估节段性肝脏质子密度脂肪分数的检查间精密度
J Magn Reson Imaging. 2014 May;39(5):1265-71. doi: 10.1002/jmri.24284. Epub 2013 Oct 17.
Zotero 插件